CONMED (CNMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Seven directors nominated for election to the board, with a recommendation to vote for all nominees.
Advisory vote on executive compensation is recommended for approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026, is recommended.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board election includes seven named nominees for directorship.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is included as a key agenda item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CONMED
- Accelerated growth, global expansion, and innovation drive strong outlook and margin gains.CNMD
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 delivered 6.0% organic sales growth, higher margins, and raised EPS guidance.CNMDQ2 2026
- All proposals, including Director elections and auditor ratification, were approved by majority vote.CNMDAGM 2026
- Net income and margins rose despite a 1.3% sales drop; organic growth outlook improved.CNMDQ1 2026
- 2026 guidance targets $1.345–$1.450B revenue and $4.25–$4.45 EPS, led by innovation and portfolio focus.CNMD44th Annual J.P. Morgan Healthcare Conference
- Q3 sales up 4.0%–4.3%, adjusted EPS up 16.7%, with CEO transition and hurricane impacts.CNMDQ3 2024
- Supply chain recovery, strong AirSeal performance, and margin growth drive a positive outlook.CNMD2024 Wells Fargo Healthcare Conference
- Q2 sales and margins improved, but full-year guidance was reduced amid supply chain delays.CNMDQ2 2024
- 2025 guidance targets 4–6% revenue growth and $4.25–$4.40 adjusted EPS, with supply chain and currency headwinds.CNMDQ4 2024